Back to top
more

Urovant Sciences Ltd. (UROV)

(Delayed Data from NSDQ)

$10.11 USD

10.11
85,656

+0.39 (4.01%)

Updated Sep 18, 2020 04:00 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.44%
2Buy17.91%
3Hold9.42%
4Sell4.91%
5Strong Sell1.79%
S&P50010.66%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 22% (197 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Balance Sheet

Research for UROV

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Urovant Sciences Ltd falls in the month of March.

All items in Millions except Per Share data.

3/31/2020 3/31/2019 3/31/2018 3/31/2017 3/31/2016
Assets          
Cash & Equivalents 52 86 7 5 NA
Receivables 0 0 0 0 NA
Notes Receivable 0 0 0 0 NA
Inventories 0 0 0 0 NA
Other Current Assets 6 13 5 0 NA
Total Current Assets 58 99 12 5 NA
Net Property & Equipment 1 1 1 0 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 0 0 0 0 NA
Intangibles 0 0 0 0 NA
Deposits & Other Assets 1 1 0 0 NA
Total Assets 63 100 13 5 NA
Liabilities & Shareholders Equity 3/31/2020 3/31/2019 3/31/2018 3/31/2017 3/31/2016
Notes Payable 0 0 0 0 NA
Accounts Payable 2 2 1 0 NA
Current Portion Long-Term Debt 0 0 0 0 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 22 10 4 0 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 7 0 1 1 NA
Total Current Liabilities 31 12 6 1 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 0 0 0 0 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 87 14 0 0 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 0 0 0 0 NA
Minority Interest (Liabilities) 0 0 0 0 NA
Total Liabilities 121 25 6 1 NA
Shareholders Equity 3/31/2020 3/31/2019 3/31/2018 3/31/2017 3/31/2016
Preferred Stock 0 0 0 0 NA
Common Stock (Par) 0 0 0 0 NA
Capital Surplus 264 250 73 31 NA
Retained Earnings -322 -176 -64 -27 NA
Other Equity 0 0 -1 0 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity -58 75 7 4 NA
Total Liabilities & Shareholder's Equity 63 100 13 5 NA
Total Common Equity -58 75 7 4 0
Shares Outstanding 30.50 30.30 NA NA NA
Book Value Per Share -1.90 2.47 0.00 0.00 0.00

Fiscal Year End for Urovant Sciences Ltd falls in the month of March.

All items in Millions except Per Share data.

6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Assets          
Cash & Equivalents 63 52 132 68 63
Receivables 0 0 0 0 0
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 9 6 10 9 8
Total Current Assets 72 58 142 77 71
Net Property & Equipment 1 1 1 1 1
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 1 1 1 4 4
Total Assets 78 63 148 82 76
Liabilities & Shareholders Equity 6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Notes Payable 0 0 0 0 0
Accounts Payable 0 2 2 2 3
Current Portion Long-Term Debt 0 0 44 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 23 22 15 10 8
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 7 7 0 0 0
Total Current Liabilities 31 31 62 12 11
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 128 87 87 43 14
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 3 3
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 163 121 152 58 29
Shareholders Equity 6/30/2020 3/31/2020 12/31/2019 9/30/2019 6/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 267 264 266 253 251
Retained Earnings -353 -322 -271 -230 -204
Other Equity 1 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity -85 -58 -4 24 48
Total Liabilities & Shareholder's Equity 78 63 148 82 76
Total Common Equity -85 -58 -4 24 48
Shares Outstanding 31.10 30.50 30.50 30.30 30.30
Book Value Per Share -2.73 -1.90 -0.15 0.78 1.57